Clinical trial · Observational
Molecular, Pathologic and MRI Investigation of the Prognostic and Redictive Importance of Extramural Venous Invasion in Rectal Cancer (MARVEL) Trial
Molecular, Pathologic and MRI Investigation of the Prognostic and Redictive Importance of Extramural Venous Invasion in Rectal Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Extramural venous invasion (EMVI) is the spread of microscopic tumour cells into the veins around the tumour. Rectal cancer treatment has improved greatly over recent years. However, it is important for us to learn as much about the tumours as possible in order to develop newer therapies. Current treatments may benefit from new genetic information relating to the cancer. We hope to identify genetic differences in certain types of rectal cancer which will allow future treatments.
Conditions
Conditions (16)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Adenocarcinoma | Adenocarcinoma | ONTOLOGY_EXACT | 0.90 |
| Adenocarcinoma, Mucinous | Mucinous Adenocarcinoma | ONTOLOGY_EXACT | 0.98 |
| Carcinoma | Carcinoma | ONTOLOGY_EXACT | 0.98 |
| Colorectal Neoplasms | Colorectal Neoplasm | ONTOLOGY_EXACT | 0.98 |
| Digestive System Diseases | — | UNRESOLVED | — |
| Digestive System Neoplasms | Digestive System Neoplasm | ONTOLOGY_EXACT | 0.98 |
| Gastrointestinal Diseases | — | UNRESOLVED | — |
| Gastrointestinal Neoplasms | Digestive System Neoplasm | ALIAS |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (2)
- label
- Group 1
- description
- Patients with mrEMVI positive rectal cancer
- label
- Group 2
- description
- Patients with mrEMVI negative rectal cancer
Primary outcomes (1)
- measure
- The primary endpoint will be time to relapse pertaining to the primary objective of relapse rate at 1 year and 3 years.
- timeFrame
- 3 years
Secondary outcomes (2)
- measure
- Response rates (in terms of mrTstage, mrN stage, involvement of CRM (circumferential resection margin) and mrTRG (tumour regression grade)) in addition to recurrence rates at 1 year and 3 years.
- timeFrame
- 3 years
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Locally advanced primary rectal cancer (requiring pre-operative treatment); diagnosed on tissue biopsy 2. Adult patients - over 18 years 3. Able to undergo curative (TME) surgery 4. Able to undergo MRI and CT with relevant contrast agent 5. Able to undergo LCRT Exclusion Criteria 1. Metastatic disease at presentation 2. Emergency diagnosis/treatment 3. Unable to undergo staging (MRI and CT) or treatment procedures (LCRT/surgery)
References
Publications (0)
Data not yet available